Although pleiotropy, which is defined as multiple effects derived from a single gene, was recognized many years ago, and considerable progress has since been achieved in this field, it is not very clear how much this feature of a drug is clinically relevant. During the last decade, beneficial pleiotropic effects from hypolipidemic drugs (as in, effects that are different from the primary ones) have been associated with reduction of cardiovascular risk. As with statins, the agonists of peroxisome proliferator-activated receptors (PPARs), niacin and fibrates, have been suggested to exhibit pleiotropic activity that could significantly modify the outcome of a cardiovascular ailment. This review examines findings demonstrating the impacts of treatment with hypolipidemic drugs on cardiac response to ischemia in a setting of acute ischemia-reperfusion, in relation to PPAR activation. Specifically, it addresses the issue of susceptibility to ischemia, with particular regard to the preconditioning-like cardioprotection conferred by hypolipidemic drugs, as well as the potential molecular mechanisms behind this cardioprotection. Finally, the involvement of PPAR activation in the mechanisms of non-metabolic cardioprotective effects from hypolipidemic drugs, and their effects on normal and pathologically altered myocardium (in the hearts of hypertensive rats) is also discussed.

b Institute of Normal and Pathological Physiology Slovak Academy of Sciences and Centre of Excellence of SAS NOREG Bratislava Slovak Republic

c Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovak Republic

e School of Biology Aristotle University of Thessaloniki Thessaloniki Greece

Institute for Heart Research Slovak Academy of Sciences and Centre of Excellence of SAS NOREG POB 104 Dúbravská cesta 9 840 05 Bratislava Slovak Republic

Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic

Citace poskytuje Crossref.org

European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)